Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study
Standard
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study. / Schochter, Fabienne; Rack, Brigitte; Tzschaschel, Marie; Polasik, Arkadius; Andergassen, Ulrich; Trapp, Elisabeth; Alunni-Fabbroni, Marianna; Schneeweiss, Andreas; Müller, Volkmar; Pantel, Klaus; Gade, Jörg; Lorenz, Ralf; Rezai, Mahdi; Tesch, Hans; Soeling, Ulrike; Fehm, Tanja; Mahner, Sven; Schindlbeck, Christian; Lichtenegger, Werner; Beckmann, Matthias W; Fasching, Peter A; Janni, Wolfgang; Friedl, Thomas W P; SUCCESS Study Group.
in: ONCOL RES TREAT, Jahrgang 41, Nr. 3, 2018, S. 93-98.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study
AU - Schochter, Fabienne
AU - Rack, Brigitte
AU - Tzschaschel, Marie
AU - Polasik, Arkadius
AU - Andergassen, Ulrich
AU - Trapp, Elisabeth
AU - Alunni-Fabbroni, Marianna
AU - Schneeweiss, Andreas
AU - Müller, Volkmar
AU - Pantel, Klaus
AU - Gade, Jörg
AU - Lorenz, Ralf
AU - Rezai, Mahdi
AU - Tesch, Hans
AU - Soeling, Ulrike
AU - Fehm, Tanja
AU - Mahner, Sven
AU - Schindlbeck, Christian
AU - Lichtenegger, Werner
AU - Beckmann, Matthias W
AU - Fasching, Peter A
AU - Janni, Wolfgang
AU - Friedl, Thomas W P
AU - SUCCESS Study Group
N1 - © 2018 S. Karger GmbH, Freiburg.
PY - 2018
Y1 - 2018
N2 - BACKGROUND: Optimal choice and sequence of endocrine treatment following adjuvant chemotherapy in postmenopausal early breast cancer patients are still under discussion and treatment stratification factors are missing.PATIENTS AND METHODS: Postmenopausal women with HER2-negative, hormone receptor-positive tumors and persisting circulating tumor cells (CTCs; assessed using the FDA-approved CellSearch® System, Janssen Diagnostics, LLC) after chemotherapy were randomized to 2 years of tamoxifen followed by 3 years of exemestane (tamoxifen-exemestane group, n = 54) or 5 years of exemestane (exemestane-only group, n = 54). CTCs were again assessed after the first 2 years of endocrine treatment. In addition, safety data were compared between the 2 groups.RESULTS: The 2 groups were well-balanced with regard to baseline characteristics. The CTC clearance rate after 2 years was 89% in the exemestane-only group and 97% in the tamoxifen-exemestane group (exact Fisher test, p = 0.36). The safety profile showed good tolerability with few grade 3 or 4 adverse events in both groups.CONCLUSION: The similar CTC clearance rate after 2 years of endocrine therapy with exemestane or tamoxifen, and the safety profiles obtained may indicate comparable efficacy and tolerability of both endocrine treatment regimens. However, these results have to be confirmed by final survival and safety analysis.
AB - BACKGROUND: Optimal choice and sequence of endocrine treatment following adjuvant chemotherapy in postmenopausal early breast cancer patients are still under discussion and treatment stratification factors are missing.PATIENTS AND METHODS: Postmenopausal women with HER2-negative, hormone receptor-positive tumors and persisting circulating tumor cells (CTCs; assessed using the FDA-approved CellSearch® System, Janssen Diagnostics, LLC) after chemotherapy were randomized to 2 years of tamoxifen followed by 3 years of exemestane (tamoxifen-exemestane group, n = 54) or 5 years of exemestane (exemestane-only group, n = 54). CTCs were again assessed after the first 2 years of endocrine treatment. In addition, safety data were compared between the 2 groups.RESULTS: The 2 groups were well-balanced with regard to baseline characteristics. The CTC clearance rate after 2 years was 89% in the exemestane-only group and 97% in the tamoxifen-exemestane group (exact Fisher test, p = 0.36). The safety profile showed good tolerability with few grade 3 or 4 adverse events in both groups.CONCLUSION: The similar CTC clearance rate after 2 years of endocrine therapy with exemestane or tamoxifen, and the safety profiles obtained may indicate comparable efficacy and tolerability of both endocrine treatment regimens. However, these results have to be confirmed by final survival and safety analysis.
KW - Journal Article
U2 - 10.1159/000485566
DO - 10.1159/000485566
M3 - SCORING: Journal article
C2 - 29490302
VL - 41
SP - 93
EP - 98
JO - ONCOL RES TREAT
JF - ONCOL RES TREAT
SN - 2296-5270
IS - 3
ER -